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ABSTRACT
Tumor hypoxia is a well-recognized driver of resistance to traditional cancer
therapies such as chemotherapy and radiation therapy. We describe development
of a new nanoconstruct composed of gold nanorods (GNRs) conjugated to carbonic
anhydrase IX (CAIX) antibody that specifically binds to CAIX, a biomarker of hypoxia,
to facilitate targeting tumor hypoxic areas for focused photothermal ablation.
Physicochemical characterization studies confirmed the size, shape, monodispersity,
surface charge, and serum stability of the GNRs. Enzyme-linked immunosorbent assays
and cellular binding and uptake studies confirmed successful conjugation of antibody
to the GNRs and specificity for CAIX. Near-infrared irradiation of CAIX-overexpressing
cells treated with GNR/anti-CAIX resulted in significantly higher cell death than
cells treated with control GNRs. In vivo biodistribution studies using hyperspectral
imaging and inductively coupled plasma mass spectrometry confirmed intravenous
administration results not only in greater accumulation of GNR/anti-CAIX in tumors
than control GNRs but also greater penetration into hypoxic areas of tumors. Nearinfrared ablation of these tumors showed no tumor regression in the sham-treated
group, regression but recurrence in the non-targeted-GNR group, and complete tumor
regression in the targeted-GNR group. GNR/anti-CAIX nanoconstructs show promise
as hypoxia targeting and photothermal ablation agents for cancer treatment.

from normal cells, causing significant adverse effects
in patients. Nanoparticle-based photothermal ablation
therapy assisted by near-infrared (NIR) laser is an evolving
area of interest with the potential to eliminate large tumors,
reduce cancer resistance and prevent recurrence [1–3]. The
basic principle behind photothermal ablation therapy is
that heat generated from plasmon resonance of atoms on
the surface of nanoparticles illuminated with NIR light can

INTRODUCTION
A major public health concern and a leading cause
of death, cancer, has motivated scientists to explore
adjunctive or alternative interventions to standard
treatments, such as surgery, radiation therapy, and
chemotherapy. Standard cancer treatments can be highly
toxic to healthy tissues without differentiating malignant
www.oncotarget.com
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be used to destroy cancer cells. Strong optical absorption
and high efficiency of photothermal conversion at the
cancer site are critical to the success of this therapy.
An ideal metal nanostructure to be used in
photothermal ablation therapy should have effective delivery,
strong and tunable surface plasmon resonance absorption in
the NIR, a low toxicity profile, and selectivity in targeting
cancer cells. Noble metal nanoparticles in general, and gold
and silver analogs in particular, have attracted extensive
interest and led to the development of a wide variety of
nanocarriers owing to their fulfillment of many of the above
properties. Substantial effort has been made to develop gold
nanoparticles of various shapes and with various surfaces;
nanospheres, nanorods and nanoshells have been broadly
applied in this type of therapy [1–3]. Among them, gold
nanorods (GNRs) have attracted particular attention for their
efficiency of photothermal activation and smaller size than
gold nanoshells for NIR activation [3–5]. However, poor
accumulation of these nanoparticles in solid tumors remains
a significant challenge for photothermal ablation therapy [6].
Increasing attention has been focused on targeting
specific pathways in the growth and development of
tumors, especially the tumor microenvironment [7–12], as
a way to improve the uptake of nanoparticles by tumors.
Most tumors develop areas of hypoxia as proliferating
cells outgrow the new vasculature that feeds them oxygen
and nutrients, resulting in a gradient of increasing hypoxia
that extends from the feeding vessel [13]. Tumor hypoxia
usually occurs at a distance of 100~200 μm from blood
vessels and is a key factor predicting the response of
tumors to irradiation; hypoxic cells are up to three times
more resistant to radiation than normoxic cells because
full radiosensitization requires the presence of endogenous
oxygen that is ionized and fixes DNA damage [13, 14].
Hypoxia inducible factor 1 (HIF-1), a key transcription
factor, is critically involved in the transcription of a spectrum
of genes that regulate cellular survival under hypoxic
conditions. Carbonic anhydrase IX (CAIX) is one such
metalloenzyme, the expression of which is exclusively
upregulated by activated HIF-1 [15]. CAIX is a member
of the carbonic anhydrase family that catalyzes the rapid
conversion of carbon dioxide to bicarbonate and protons.
Presenting in few normal human tissues, the CAIX protein
is highly expressed in hypoxic zones within human epithelial
tumors derived from tissues that ordinarily do not express this
isozyme [16]. The expression of CAIX is generally very low
in some carcinoma cell lines under normoxia, but high levels
can be induced by hypoxia or anoxia to generate a moderately
alkaline intracellular pH (pHi) and an increasingly acidic
extracellular pH (pHe) which are favorable for tumor cell
growth and invasiveness [17]. Genetic depletion of CAIX in
some carcinoma cells and human cancer xenografts reduces
or attenuates primary tumor growth and inhibits metastasis
formation [18, 19]. Unlike HIF-1, CAIX is a transmembrane
protein, allowing efficient access by targeting and therapeutic
agents. Therefore, CAIX constitutes a promising diagnostic
www.oncotarget.com

biomarker of hypoxic tumor regions and an enticing target
for augmenting response to the standard radiotherapy and
chemotherapy. Correlation of its overexpression with poor
response to classical chemotherapy and radiation makes
CAIX an attractive molecular target for anticancer drug
development [13]. CAIX-specific therapeutic modalities,
monoclonal antibodies (mAb) and small molecule inhibitors,
are being exploited to directly target the catalytic activity of
CAIX for enhanced treatment efficacy [20].
Convenient properties of anisotropic GNRs have
created strong interest in the development of antibodytargeted nanorods for a number of biomedical applications,
including photothermal treatment combined with antibody
therapy. By conjugating GNRs with anti-CAIX mAb, we
expect to be able to ferry more GNRs to the most desirable
location within tumors - that is, hypoxic areas that are
more resistant to standard therapies. Focal targeting of
these areas can address a source of treatment resistance
more effectively than passive targeting of the entire tumor.
In this study, we successfully fabricated a stable GNR/
anti-CAIX nanoconstruct and tested its binding affinity
and specificity to CAIX-positive cancer cells. We used
photothermal ablation to document therapeutic efficacy in
vitro and in vivo, demonstrating that this GNR/anti-CAIX
nanoconstruct, combined with NIR laser offers a viable
new photothermal intervention to combat tumor hypoxia.

RESULTS
Characterization of GNRs and GNR conjugates
TEM revealed rod-like GNRs with lengths of ~30 nm
and diameters of ~10 nm (Figure 1A). Zetasizer measurements
confirmed the length of the GNRs at ~30 nm and their zeta
potential of 60 mV (with cetyl trimethylammonium bromide,
CTAB coating). The UV-Vis spectra of GNR-CTAB exhibited
two prominent surface plasmon resonance peaks, one in
the visible range at ~510 nm and another more prominent
peak at ~760 nm (Figure 1B). A bifunctional polyethylene
glycol (PEG), ortho-pyridyldisulfide-polyethylene glycol
2000-N-hydroxysuccinimide ester (OPSS-PEG2K-SVA), was
used to conjugate GNRs to anti-CAIX [1, 12, 21]. Compared
with the GNR-CTAB and bare GNR (after centrifugation),
shifts and changes of the NIR absorption, hydrodynamic
diameter, and zeta potential of conjugated GNRs confirmed the
success of each surface modification step (Table 1). A 15 nm
blue shift of the longitudinal peak without peak broadening was
noted with GNR-PEG compared to GNR-CTAB. Conjugation
of anti-CAIX mAb results in a further 9 nm red shift of the
longitudinal peak compared to the GNR-PEG.
The observed spectral shifts can be attributed
to changes in the refractive index of the nanorods’
surrounding environment [22]. The short-term stabilities
of GNR, GNR-PEG and GNR/anti-CAIX were tested in
1X PBS buffer overnight, with optical spectra obtained
afterward. As Figure 1C shows, the “as-made” GNR26557
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Table 1: Size and zeta potential of GNRs, PEG-coated, and antibody conjugated GNRs
Surface ligands

Hydrodynamic diameter (nm)

Zeta potential (mV)

CTAB

32.7 ± 2.5

68.1 ± 9.1

After centrifuge

24.7 ± 0.3

55.5 ± 3.4

PEG-2K-SH protecting

32.0 ± 2.1

23.1 ± 3.1

OPSS-PEG-anti-CA IX

34.9 ± 1.2

9.2 ± 1.3

PEG-5K-SH final protecting

47.6 ± 1.6

4.1 ± 0.6

Quantification of antibodies per nanorod

CTAB and bare GNR had peak absorption at 755 nm
and 745 nm, respectively. Overnight incubation in 1X
PBS led to bare GNR forming aggregates and losing
their peak at 745 nm, whereas GNR-PEG and GNR/
anti-CAIX remained stable with preservation of their
absorption peaks near 750 nm. These results suggested
that the conjugated GNRs will be stable when exposed to
blood, which had similar ionic strength as 1X PBS, and
are therefore suitable for preclinical studies on laboratory
animals.

The binding affinity of the GNR/anti-CAIX to
CAIX protein and the numbers of antibodies per GNR
particle were evaluated by using sandwich enzyme-linked
immunosorbent assay (ELISA) (Supplementary Figure
1). Both the anti-CAIX mAb and the GNR/anti-CAIX
conjugate showed increased binding to protein CAIX with
increasing concentration, while little binding was found
between GNR-PEG and the protein. The calibration linear

Figure 1: Characterization of GNR. (A) TEM image of GNR. (B) UV-Vis spectra of GNR at each step of conjugation. (C) UV-Vis
spectra of different GNRs after overnight incubation in 1x PBS. Bare GNR crashed while GNR-PEG and GNA/anti-CAIX were stable.
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NIR photothermal treatment in vitro

curve for absorbance vs. anti-CAIX concentration showed
an R2 of 0.997, and the curve of absorbance vs. GNR/antiCAIX concentration was also linear with an R2 of 0.999.
Based on these curves, a linear relationship was assessed
for GNR/anti-CAIX OD vs. anti-CAIX mAb concentration
(Supplementary Figure 2), and from the resulting equation
we calculated that the number of anti-CAIX per GNR to
be 5.0 ± 0.4, a value similar to previous findings [23].
In a preclinical study the therapeutic efficacy of an antiCAIX mAb conjugated drug with an average drug-toantibody ratio of n=~4 showed a positive correlation
with tumor CAIX expression level determined by
immunohistochemistry and ELISA in tumor models [24].

Having demonstrated hypoxia-specific accumulation
of GNR/anti-CAIX in cells, we then studied if this could
enhance photothermal effects in cells. As shown in Figure
3, HT29 cells incubated with GNR-PEG (0.5 OD at 760
nm) decreased little in viability as measured by MTT
assay (B), while treatment with GNR/anti-CAIX (0.5 OD
at 760 nm) alone increased cell death by 15.5% (P<0.01)
compared to control cells (C). This antibody-dependent
cell cytotoxicity (ADCC) may worked through directly
targeting the catalytic domain of CAIX, disrupting the
catalytic activity of the enzyme, including pH regulation
and thus targeting its tumorigenic functions [31]. Epitopes
of some anti-CAIX mAb fragments have showed a
direct and prompt inhibition upon CAIX of human renal
carcinoma cells in spheroid cultures [32]. Sole treatment of
anti-CAIX mAbs in HT29 colorectal xenografts affectivity
limited tumor growth after cell inoculation [33]. Moreover,
the PG domain-specific G250 mAb and its fragments have
been developed as CAIX-specific immunological tools
for an adjuvant therapy against recurrence of renal cell
carcinoma in patients [34]. The anti-CAIX mAb GT12
used in our study also binds to linear repetitive epitope
in the PG region of native CAIX. Merely laser irradiation
(12 W/cm2 for 2 mins) caused little cytotoxicity (Figure
3D). In contrast, laser irradiation in the presence of GNR/
anti-CAIX conjugates significantly reduced the viability
of HT29 cells to 64.9±9.3% (P<0.001) compared to GNR/
anti-CAIX alone (P<0.01) and GNR-PEG with radiation
treatment (P<0.05) (Figure 3F and 3E). Note that the laser
spot is about 5 mm in diameter, which is about 60% of the
growth surface in a well (96-well plate), therefore not all
the cells in a well were directly treated with laser.
Visual analysis of the cell viability was performed
by double staining HT29 cells with calcein AM (485
nm excitation, 535 nm emission) and propidium iodide
(PI, 530 nm excitation, 620 nm emission). The assay
is based on the conversion of the cell permeant nonfluorescent calcein AM dye to the fluorescent calcein
dye by intracellular esterase activity in live cells
(green), while PI is membrane-impermeant and only
intercalates its fluorescence with nucleic acids of
dead cells (red). As Figure 4 shows, irradiating cells
with up to 12 W/cm2 for 2 min caused significant cell
death upon treatment with GNR/anti-CAIX, while
the magnitude of cell death was similar in the GNRPEG treated group and the control (medium treated)
group, which suggested that retention of GNRs inside
the cells via anti-CAIX mAb conjugation mediates
efficacy of photothermal ablation. Note that we used
a low laser power (temperature increase was low)
which was further dissipated by the presence of media.
Consequently, complete destruction of cells within the
laser field was not expected and was not observed.

High specific cellular uptake of GNR/anti-CAIX
in cells
Correlation of the uptake efficacy of the GNR/antiCAIX with expression level of CAIX protein was assessed
using both normoxic and CoCl2-induced hypoxia-mimetic
conditions in HT29 cells. Co2+ replaces iron in the O2-sensing
heme proteins, locking them into the “deoxy” conformation
to induce expression of hypoxia-sensitive genes, in a manner
similar to that observed with hypoxia [25]. Maximum
uptake via receptor-mediated endocytosis of similarly sized
PEGylated gold nanoparticles coated with ligands were
reported at 2 h along with a fixed fraction of nanoparticles
exocytosed [26, 27], therefore this time point was used
for our cellular uptake studies. Silver enhancement was
utilized to probe GNRs in cells by depositing metallic silver
on the surface of GNRs until they were visible on bright
field microscopy as black spots. The protein expression
of CAIX of HT29 cells was upregulated significantly in
response to CoCl2 treatment [28]. So as Figure 2 shows, a
much higher uptake of gold was found in HT29 cells treated
with GNR/anti-CAIX in contrast with GNR-PEG and
medium control, indicating efficient targeting and successful
conjugation. Also, hypoxic status did increase intracellular
accumulation of GNRs treated with GNR/anti-CAIX at 2 h,
which is in agreement with previous studies by showing a
positive correlation between CAIX conjugates binding and
expression of CAIX in human carcinoma cells [29, 30].
Hyperspectral dark field microscopy imaging also confirmed
similar findings with the GNR/anti-CAIX group showing
strong and specific binding to HT29 cells compared to the
control group, while the GNR-PEG group only showing
non-specific binding (Supplementary Figure 3). In addition,
immunoconjugate specificity of GNR/anti-CAIX in cells has
also been demonstrated by significant differences in binding
capabilities between CAIX-positive HT29 cells and CAIXnegative NIH 3T3 cells, in which only HT29 cells labeled
with GNR/anti-CAIX showed focal cellular black deposits,
while none was observed in the NIH 3T3 cells labeled with
GNR/anti-CAIX after 2 h (silver staining images as shown in
Supplementary Figure 4).
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Figure 2: Silver staining of fixed HT-29 cells. Incubated with medium only (A and D), GNR-PEG (0.5 OD at 760 nm) in medium
(B and E), and GNR/anti-CAIX (0.5 OD at 760 nm) in medium (C and F) for 2 h. A, B and C were normal HT-29 cells; D, E and F were
HT-29 cells in the CoCl2 induced hypoxic status.

Figure 3: The survival percentage obtained for the HT29 cells after different treatment regimens. No treatments but only
medium (A) were applied as the control group which was used to evaluate other parameter on cell lethality (*p < 0.05, **p < 0.01, ***p <
0.001). The data were expressed as mean ± SEM.
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Tumor and organ uptake

relatively high uptake of GNRs in the tumor at 24 h p.i. is
mainly due to the long circulation time of PEGylated GNRs
and the enhanced permeability and retention (EPR) effect.
Notably, the gold accumulation was higher in the GNR/antiCAIX group (9.3 ± 0.8% ID/g), than the GNR-PEG group
(5.6 ± 1.4% ID/g), indicating efficient targeting as seen with
preferential accumulation of radiolabeled anti-CAIX mAb
in xenografted HT29 tumor at 24 h [39–41]. Surprisingly,
there was greater accumulation of gold in the kidney in
the GNR/anti-CAIX group (2.5 ± 0.5% ID/g) compared to
the GNR-PEG group (0.9 ± 0.2% ID/g). This may be due
to size-dependent entrapment of in the corpuscles of the
kidney mesangium [42] and/or preferential uptake of antiCAIX mAb by the kidney at 24 h [41, 43]. No difference in
gold accumulation in the lung and heart was noted between
GNR/anti-CAIX and GNR-PEG.

As a prelude to investigating the in vivo photothermal
ablation efficacy of the constructs, we first performed a
detailed biodistribution analysis of not only individual
organ and tumor accumulation of gold but also the
geographical distribution of GNRs in tumor hypoxia.
The optimal intratumoral accumulation of similarly sized
PEGylated GNRs was observed at 24 h post injection
(p.i.) in several previous studies in mouse xenograft
models [35–37]. This time point was used for subsequent
NIR photothermal treatments in vivo. Swiss Nu/Nu
mice harboring subcutaneous HT29 xenografts were
administered 100 μL of GNR-PEG or GNR/anti-CAIX
intravenously and the tumors and normal organs were
harvested 24 h later. As shown in Figure 5, the largest
fractions of gold accumulation determined by ICP-MS
were observed in the liver and spleen, consistent with the
foreign body phagocytic activity of resident macrophages
in these organs, the Kupffer cells of the reticuloendothelial
system in the liver and the macrophages and B cells of the
mononuclear phagocytic system in the spleen [38]. The

Location of GNRs in areas of tumor hypoxia
Although the biodistribution study confirmed
greater tumor accumulation of targeted GNRs than
nontargeted GNRs, this provides neither spatial

Figure 4: HT29 cell viabilities after photothermal treatment were imaged by fluorescence microscope under double
staining by calcein AM and Propidium Iodide after an NIR laser irradiation (12 W/cm2) for 2 min. Viable cells were in
green and dead and dying cells were in red. (A) cells in growth medium, (B) cells treated with laser, (C) cells treated with GNR-PEG and
laser, and (D) cells treated with GNR/anti-CAIX and laser.
www.oncotarget.com
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information on the location of targeted GNRs relative to
areas of hypoxia nor the degree of interaction of GNRs
within tissue. Therefore, we analyzed tumor tissue
sections by overlaying immunofluorescence images of
hypoxic areas identified by pimonidazole accumulation
and GNR location by hyperspectral imaging. The
characteristic spectral profiles of the tumor matrix itself
were first identified by enhanced dark field microscopy
with hyperspectral imaging of tumors from animals treated
without GNRs (Figure 6D, 7A, and 7D). After subtracting
this background from tumors from animals treated with
GNRs, the distinct dual absorbance peak spectra of
GNRs (Figure 6E for GNR-PEG and Figure 6F for GNR/
anti-CAIX that was spectrally shifted) was used to map
their locations with tumors. In parallel, in vitro spectral
profiles were also obtained of HT29 cells alone and in the
presence of GNR-PEG and GNR/anti-CAIX (Figure 6A,
6B and 6C). Furthermore, tandem fluorescence imaging
of fluorescently-labeled pimonidazole staining to identify
areas of physical hypoxia and overlay of the hyperspectral
image with the fluorescence image facilitated semiquantitative comparison of the relative amounts of
GNRs in hypoxic areas of histological sections. First,

we observed a spectral shift toward higher wavelengths
in the GNR/anti-CAIX group suggesting agglomeration
of GNRs [44, 45], possibly due to endocytosis and
aggregation in endosomes and lysosomes [46, 47].
Aggregation can be induced by coated anti-CAIX mAb
proteolysis and the low pH environment of the endosome
(pH 5.5) and lysosome (pH 4–5) [45]. Next, we observed
more right-shifted and aggregated GNRs on the dark-field
image (Figure 7C) of GNR/anti-CAIX treated tumors
than GNR-PEG treated tumors (Figure 7B) confirming
greater accumulation and internalization (with consequent
aggregation) of GNRs in this group. Consistent with the
notion that CAIX expression is more prominent in hypoxic
areas [41] and correlates well with pimonidazole uptake
[48], pimonidazole-positive areas of tumors harbored
more GNRs in the targeted GNR/anti-CAIX group (Figure
7F) than in the untargeted GNR-PEG group (Figure 7E),
where they were more randomly dispersed. No remarkable
existence and well distribution of GNRs within hypoxia
were observed in Figure 7C and 7F owing to ultrathin
histological sections and aggregates of nanoparticles.
Also, it is likely that the hyperspectral imaging was
more sensitive at detecting agglomerated particles than

Figure 5: Comparison of gold content in tissues by ICP-MS 24 h after intravenous administration of targeted (GNR/
anti-CAIX) and untargeted (GNR-PEG) GNRs in HT29-tumor-bearing mice (n=4 for both groups). The uptake of GNR/
anti-CAIX was significantly higher than GNR-PEG in xenograft tumor (*p<0.05). The biodistribution in other organs was similar for both
groups except higher uptake in the kidney for GNR/anti-CAIX.
www.oncotarget.com
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Figure 6: Hyperspectral imaging of GNRs exhibited unique spectral profiles in HT-29 cells and tumor. (A, D) Background
spectral profiles of control cells and control tumor without GNRs; (B, E) GNR-PEG in cells and tumor, respectively; (C, F) GNR/antiCAIX in cells and tumor, respectively. Spectral shifts of GNR/anti-CAIX suggesting more complex interactions between cells and tumor
tissues and GNR/anti-CAIX compared to GNR/PEG.

Figure 7: Representative 60x hyperspectral dark field images (A-C) and corresponding immunofluorescence (orange)
images of tumor hypoxia characterized by pimonidazole uptake (D-F). (A, D): negative control tissue; (B, E): GNR-PEG;

(C, F): GNR/anti-CAIX. GNRs identified by hyperspectral analysis were mapped and marked with arrows and red color in darkfield
images. Abundant and aggregated red pixels were found within hypoxic areas of GNR/anti-CAIX treated tumors compared to GNR-PEG
treated tumors.
www.oncotarget.com
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nontargeted GNRs in vivo. HT29-tumor-bearing nude mice
injected intravenously with saline, GNR-PEG, or GNR/
anti-CAIX were irradiated 24 h later with an NIR laser
(760 nm, 12 W/cm2, 2-3 min). The temperature measured
by the TRH Central probe within the tumor rapidly
reached to ~53°C within 2 to 3 min of NIR laser exposure
on the skin surface above the tumor in GNR-PEG-injected
mice and GNR/anti-CA IX-injected mice. As expected,
the absolute temperature and rate of temperature increase
were lower in the tumors of PBS (1X)-injected mice than
that in the other two groups. Other photothermal studies
using gold nanoparticles also suggested that temperature
increases of 21.5°C upto 35°C achieved efficient tumor
ablation without causing obvious toxicity [50–52]. Mice
treated with saline showed uninhibited tumor growth
after irradiation, with the mean tumor volume reaching
1000 mm3 16 days later (Figure 8A). Tumors of mice
injected with GNR-PEG or GNR/anti-CAIX, however,
were completely ablated on the day of irradiation (day 1).
Despite this complete ablation, tumors regrew slowly in
the mice treated with GNR-PEG whereas they remained

individual 30nm-long GNRs which may be below the
resolution limit of the microscope, obscured by backscatter
from other sources or attenuated by tissue densities.
Additional tissue section images have been included as
Supplementary Figure 5. A new GNR functionalization
strategy may facilitate a better distribution of GNRs in
tissue hypoxia by changing ligand exchange method [49].
Nonetheless, taken together with the greater quantities of
gold in the GNR/anti-CAIX group than the GNR-PEG
group (on ICP-MS analysis), the geographic distribution
results of the hyperspectral imaging study confirm the
preferential accumulation of targeted particles in hypoxic
areas of tumors.

NIR photothermal treatment in tumor-bearing
mice
Having confirmed selective and preferential
accumulation of GNR/anti-CAIX within areas of tumor
hypoxia, we then evaluated the therapeutic effect of
photothermal ablation of tumors laden with targeted and

Figure 8: Photothermal ablation via near infrared irradiation of HT29 tumors 24-h after tail-vein injection of saline
(n=3), GNR-PEG (n=5, OD=20) or GNR/anti-CAIX (n=7, OD=20). (A) Tumor volume plotted over time for all three groups.

Data are presented as mean ± SEM. (B) Images of representative mice in each group prior to treatment, one day after treatment, and 16 days
after treatment. No tumor regression in the saline-treated group; regression but recurrence of tumor in the GNR-PEG treated group; and
complete tumor regression in the GNR/anti-CAIX treated group. (C) Body weight of mice in each group. No statistical difference between
the three groups.
www.oncotarget.com
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undetectable in the GNR/anti-CAIX group (Figure 8B).
Notably, although the ablation scar was small in the
saline-treated group, large in the GNR-PEG group and
most prominent in the GNR/anti-CAIX group, body
weights of mice in all groups remained largely unchanged
indicating the lack of any overt acute toxicity (Figure 8C).
Collectively, these findings demonstrate that GNR/antiCAIX constructs can improve the antitumor effectiveness
of NIR laser photothermal treatment while retaining a mild
toxicity profile.

cells between the vascular endothelium and deeper areas
away from the vessel. Thus, nanoparticles are possible to
penetrate to these depths from the tumor vasculature even
if they are larger than oxygen molecules, as long as they
are not consumed by intervening cells.
Treatment conditions in our study, including the
threshold laser power density (12 W/cm2) and exposure
time (2-3 min) at which GNR/anti-CAIX induced tumor
regression were similar to some previous reports of in
vivo NIR irradiation that used other NIR-absorbing gold
nanostructures injected via tail veins, such as nanorods (2
W/cm2, 5 min) [2], nanoshells (4 W/cm2, 3 min) [1], and
nanospheres (3 W/cm2, 5 min) [53]. The lowest NIR laser
dose that produced tumor ablation with GNR that we could
find was 0.9-1.1 W/cm2 with a 6-min-long irradiation
[35]; however, the GNRs in that study were administered
intratumorally. Notably, intravenous administration of 100
μL of 20 OD particles in our study compares favorably
with 100 μL of 50-120 OD particles utilized in other
studies [1, 2, 53]. Collectively, our findings, juxtaposed
with previous studies, suggest that GNRs conjugated
to anti-CAIX can be used as selective and efficient
photothermal agents for tumor ablation using a lowenergy, harmless NIR laser with brief exposure times that
cause minimal damage to surrounding normal tissue. Our
improved therapeutic efficacy could result from better
targeting of GNR to tumor hypoxia via the guidance of
anti-CAIX. Furthermore, eliminating the hypoxic fraction
of tumor cells within tumors and forestalling recurrences
via CAIX targeted nanoparticle approaches could be a
potent adjunct to conventional therapies that often fail
due to the recalcitrance of hypoxic cells to these therapies.
Understandably, this approach to targeting tumors and
overcoming treatment resistance can be applied broadly
across all tumor types without the need for decorating

DISCUSSION
In this study, we demonstrated that decoration of
~30 × 10 nm GNRs with anti-CAIX antibodies permits
preferential targeting of cells harboring cell-surface CAIX
protein that then facilitates selective ablation of these cells
upon NIR irradiation in vitro. When administered in vivo,
these targeted constructs accumulate in greater quantities
in tumors than untargeted GNRs and selectively sequester
within hypoxic areas where their internalization in CAIXoverexpressing cells results in intracellular aggregation.
Photothermal ablation of HT29 tumors in mice treated
with GNR/anti-CAIX resulted in sustained and durable
complete tumor regression whereas tumors treated with
GNR-PEG showed an immediate regression but eventually
regrowth, possibly due to the persistence of treatmentresistant hypoxic cells. A frequent source of puzzlement is
the assumption that if even a small molecule like oxygen
is unable to reach a hypoxic cell a larger nanoparticle
would have no ability to reach this cell. However, hypoxia
within a tumor is not strictly a function of inability of
oxygen to diffuse far from the feeding vessel, but rather
is a combination of diffusion-limited restriction of oxygen
transport and consumption of oxygen by intervening

Figure 9: Preparation of hypoxia-targeted GNRs. The conjugation of GNRs with anti-CAIX antibody via bi-functional crosslinker
OPSS-PEG-SVA.
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GNRs with moieties homing onto tumor-specific epitopes
that vary across tumor types. Therefore, this could be a
turn-key class solution to the clinical challenge of hypoxic
treatment resistance across multiple tumor types.

microscope (Hitachi High Technologies America, Inc.,
Dallas, TX).

MATERIALS AND METHODS

GNRs and anti-CAIX were conjugated in a fivestep fashion as shown in Figure 9. First, anti-CAIX was
conjugated to OPSS-PEG2k-SVA by mixing them at 1:1.5
molar ratios overnight at 4°C [12]. Second, the GNR
suspension (5 mL, 0.5 OD at peak wavelength as made
above) was obtained by centrifugation at 10,000 rpm for
30 min to remove the extra CTAB [55]. Third, the particles
were semi-stabilized by adding a very small amount of
PEG-2K-SH (1 μM). Fourth, 30 μL of the OPSS-PEGCAIX was immediately added into the GNR suspension
(50:1 molar ratio) and the mixture was placed on a shaker
at room temperature for 1 h, allowing the OPSS group to
conjugate to the gold surface of the particles. Finally, PEG5K-SH was mixed with GNR/anti-CAIX at a molar ratio
of 100,000:1 to backfill the surface of GNR and nearly
neutralize the surface charge of GNR, thereby increasing
their stability and circulatory half-life. The mixture was
centrifuged at 10,000 rpm for 10 min to remove the free
OPSS-PEG-CAIX and extra PEG-5K-SH, and the pellets
were re-suspended in 1X PBS (pH 7.4). Changes in UVVis absorbance, size, and zeta potential were assessed
at each step of the conjugation procedure with a UVVis spectrophotometer and Zetasizer as described in the
preceding paragraph.

Preparation of GNR conjugates

Materials
Gold (III) chloride hydrate (HAuCl4), CTAB,
sodium borohydride (NaBH4), L-ascorbic acid, silver
nitrate (AgNO3), sodium sulfate (Na2S), and bovine serum
albumin (BSA) were purchased from Sigma-Aldrich
(St. Louis, MO, USA). CAIX recombinant protein and
secondary goat anti-mouse IgG antibody (HRP), were
purchased from Novus Biologicals (Litttleton, CO, USA).
Mouse monoclonal CAIX antibody GT12 was purchased
from GeneTex (Irvine, CA, USA). PEG 2000 thiol (PEG2K-SH), PEG 5000 thiol (PEG-5K-SH) and bifunctional
OPSS-PEG2K-SVA were purchased from Laysan Bio,
Inc (Arab, AL, USA). Human colon adenocarcinoma
cell line HT29 was purchased from the American Type
Culture Collection (Manassas, VA). DMEM medium with
4.5 g/L glucose, L-glutamine & sodium pyruvate and
Dulbecco’s phosphate-buffered saline 1X without calcium
and magnesium (1X DPBS) were purchased from Corning
(New York, NY, USA). Phosphate-buffered saline 1X
without calcium and magnesium (1X PBS) was purchased
from Hyclone laboratories, Inc (Logan, Utah, USA).

Sandwich enzyme-linked immunosorbent assay
(ELISA)

GNR synthesis
GNRs were synthesized via the seed-mediated
growth method [54]. Briefly, 250 μL of 10 mM HAuCl4
was dissolved in 7.5 mL of 10 mM CTAB solution by
stirring, and 600 μL of ice-cold NaBH4 (10 mM) was
quickly added to the solution; after 2 h at 30°C, 2- to 5-nm
gold nanoparticles were formed as a seed solution. A
growth solution was prepared by mixing 40 mL of CTAB
(10 mM), 1.7 mL of HAuCl4 (10 mM), 250 μL of AgNO3
(10 mM) and 270 μL of L-ascorbic acid (100 mM), after
which 840 μL of seed solution was added into growth
solution for 30 min to form GNRs until 100 μL of 10
mM Na2S was added to stop the reaction. The final GNR
suspension was characterized by an ultraviolet/visible
wavelength (UV-Vis) spectrophotometer (U-0080D,
Hitachi, Schaumburg, IL, USA) and dynamic light
scattering/zeta potential analyzer (Nano-ZS Zetasizer,
Malvern, Westborough, MA, USA). The size and shape
of GNRs were examined by transmission electron
microscopy (TEM). Samples were prepared by placing
one drop of the GNR suspension on a 200-mesh copper
grid with lacey carbon (SPI Supplies, West Chester, PA),
and drying in a vacuum oven overnight, followed by
imaging with a Hitachi S-4800-II transmission electron
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A sensitive sandwich ELISA was developed for
determining the number of captured anti-CAIX per
GNR (Supplementary Figure 1). CAIX protein was
coated on 96-well plates at 0.1 μg/well. After incubation
overnight at 4°C, the plates were washed with washing
buffer (1X PBS with 0.05% Tween 20), and then blocked
with blocking buffer (1X PBS with 2% BSA) at room
temperature for 2 h. The blocking buffer was removed,
and serial dilutions of anti-CAIX, GNR-PEG, or GNR/
anti-CAIX (prepared with blocking buffer) were added in
triplicate. The starting concentration of anti-CAIX was
0.11 μg/mL and GNR-PEG and GNR/anti-CAIX were
of 5 OD at ~760 nm. After 1 h of incubation at room
temperature, the ELISA plates were washed five times
with washing buffer. The binding affinity of anti-CAIX
was detected by adding HRP, followed by 1 additional
hour of incubation and five washes. At that time 100
μL of substrate solution was added to each well and
the plates incubated for 10~15 min in the dark. Finally,
100 μL of stop solution was added to each well and
incubated for 15 min. The absorbance was then read at
450 nm with a DTX 880 multi-mode detector (Beckman
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Coulter, South Kraemer Boulevard Brea, CA). The
resulting absorbance intensities were plotted against antiCAIX concentrations to get a standard curve allowing
calculation of the amount of anti-CAIX attached to GNR.

After 2 h of incubation, cells were rinsed three times with
DPBS to remove any free GNRs and replenished with
fresh medium. An NIR laser, at a wavelength of 760 nm
(to overlap the spectral absorption of the GNRs) with a
spot-size of ~5 mm in diameter and power density of 12
W/cm2 was used to irradiate each well for 2 min. 20 μL
of MTT solution (5 mg/mL) was added to each well of
96-well plate and incubated for an additional 4 h, while
2.5 μM Propidium Iodide (PI, Life Technologies) and
3 μM calcein AM (Cell Biolabs) were added to 24-well
plates to evaluate viability by fluorescence microscopy
(DMI600 B; Leica). At the end of the incubation time,
formazan crystals were dissolved by 200 μL dimethyl
sulfoxide (DMSO) and the plate was placed on the orbital
shaker for 10 min. Finally, the plates were read at 590 nm
with a 630 nm reference using a DTX 880 multi-mode
detector. The viability rate (%) of cells in different groups
was calculated by the following formula: viability rate =
(average absorbance of treated group/average absorbance
of the control group) ×100%.

Cellular uptake of coated GNRs
The treatment group of HT29 cells was cultured
on Poly-D-lysine coated cover glass (NeuVitro) in wells
under standard conditions and grown to ~80% confluence,
followed by treatment with cobalt (II) chloride (CoCl2)
at a final concentration of 100 μM overnight to induce
hypoxia [56], while the control group only exposed
to growth medium throughout. Growth medium was
removed and cells were rinsed three times with 1x DPBS
(pH 7.2) before treatment with GNR-PEG (500 μL/well of
0.5 OD at 760 nm), GNR/anti-CAIX (500 μL/well of 0.5
OD at 760 nm) or media alone. After incubation for 2 h,
the wells were rinsed three times with ice-cold 1x DPBS
and chemically fixed with 2% glutaraldehyde in 1x DPBS
at 4°C for overnight, then rinsed four times with deionized
water. Both of silver staining and hyperspectral dark-field
imaging were incorporated to measure cellular uptake of
GNRs in HT29 cells. Silver enhancement of binding was
performed with the Silver Enhancer kit (SE100, Sigma)
according to the manufacturer’s protocol. After ~5 min
the development was stopped by washing with deionized
water and 2.5% sodium thiosulfate solution. The intensity
of the silver enhanced label was documented with a
bright field microscope. The CytoViva Hyperspectral
Imaging System (CytoViva Inc., Auburn, AL, USA)
featuring enhanced dark field microscopy was used to
locate GNRs in cell slides. Hyperspectral profiles were
acquired using a Pixelfly camera and visualized using
ENVI 4.8 software. To confirm the identity of GNRs,
we used z-spectral profiles to create spectral libraries of
each section containing GNRs and compared to that of
the negative control. Then, spectra extracted from tissue
slices that overlapped with the spectral profile of GNRs
in solution with two absorption peaks at ~510 nm and ~
760 nm (axial and longitudinal plasmon resonance peaks,
respectively) were chosen as representative of GNRs in
cells. The Spectral Angle Mapper Classification (SAM)
procedure was used to mark pixels within images with
characteristic GNR spectra.

Biodistribution study
Eight (8) six-week-old male Swiss Nu/Nu mice
purchased from the in-house MD Anderson colony were
inoculated by subcutaneous injection of ~2 × 106 HT29
cells in the right thigh, according to a protocol approved
by the IACUC at MD Anderson Cancer Center. Mice were
injected with either 100 μL of GNR-PEG (n=4,20 OD) or
100 μL of GNR/anti-CAIX (n=4,20 OD) once the mean
tumor size reached a diameter of ~7mm. The animals
were euthanized at 24 h p.i., and tumors and organs
(liver, kidney, spleen, heart and lung) were collected for
assessment. The tumors and organs were washed in iced
1x PBS buffer, frozen, and then lyophilized overnight.
Each dried tissue sample was weighed, dissolved in 1
mL of aqua regia then diluted with 9 mL of 2% hydrogen
chloride (HCl) for a total volume of 10 mL. Tissue debris
was removed using 0.1 μm syringe-driven filters (MillexVV from EMD Millipore). The gold content was analyzed
by ICP-MS (Varian 810-MS, Agilent, Santa Clara, CA)
at the Inductively Coupled Plasma Mass Spectrometry
Analytical Lab of University of Houston. Results were
expressed as a percentage of the injected dose per gram
(%ID/g).

In vitro NIR photothermal laser treatment

Histological processing and imaging

The cellular response to treatment with GNR-PEG
or GNR/anti-CAIX and laser irradiation was assess using
the MTT and fluorescence-based cell viability assays.
Briefly, 1×104 HT29 cells in 100 μl of complete medium
were seeded in a 96-well plate or 24-well plate and
incubated overnight. Either GNR-PEG or GNR/anti-CAIX
at a final concentration of 0.5 OD in culture treatment
medium was added, with blank medium used as a control.

As previously described, Swiss Nu/Nu mice were
xenografted with HT29 tumors, following an animal
protocol approved by the IACUC at MD Anderson Cancer
Center. Three (3) mice each were intravenously injected
with either 100 μL of GNR-PEG (20 OD) and 100 μL of
GNR/anti-CAIX (20 OD) and one (1) mouse received
saline alone when the mean tumor size reached ~7 mm. At
24 h p.i. mice were then administered 2.5 mg pimonidazole
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(Hypoxyprobe, Burlington, MA, USA) intravenously and 1
h later administered 0.4 mg Hoechst 33342 (Sigma-Aldrich)
intravenously, followed immediately by euthanasia.
Tumors were excised and embedded in optimal cutting
temperature compound for frozen section analysis. Four
to five-micron sections were stained overnight (at 4°C)
with anti-pimonidazole primary antibody (Hypoxyprobe,
Burlington, MA, USA) diluted (1:50) in antibody diluent
(Dakocytomation) followed by 1 h incubation (at 20°C)
with Alexa Fluor 555 labeled anti-mouse secondary
antibody (ThermoFisher, Waltham, MA, USA) using a
1: 100 dilution. GNRs in prepared tissue sections were
identified by hyperspectral dark field imaging using the
same parameter settings described in the cellular uptake
study. The Alexa Fluor 555 fluorescence was captured by a
Dage camera coupled with dual mode fluorescence module
with appropriate excitation/emission filters.

sandwich enzyme-linked immunosorbent assay; EPR,
enhanced permeability and retention; GNRs, gold
nanorods; HIF-1, hypoxia inducible factor 1; ICP-MS,
inductively coupled plasma mass spectrometry; mAb,
monoclonal antibodies; NIR, near-infrared; PBS, phosphatebuffered saline; PEG, polyethylene glycol; OPSSPEG2K-SVA, ortho-pyridyldisulfide-polyethylene glycol
2000-N-hydroxysuccinimide ester pHe, extracellular pH;
pHi, intracellular pH; p.i., post-injection; PI, propidium iodide
TEM, transmission electron microscopy; UV-Vis, ultraviolet/
visible wavelength
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In vivo NIR photothermal laser treatment
Fifteen (15) 8-week-old female CR ATH HO nude
mice (Charles River) with HT29 tumors engraftment,
following an animal protocol approved by IACUC at Texas
Southern University, were randomly assigned to one of
three treatment groups when the mean tumor size reached
~7 mm. Mice in all three groups were anesthetized and
administered via tail vein with 100 μL of saline (n=3 mice),
100 μL of GNR-PEG (n=5,20 OD) or 100 μL of GNR/
anti-CAIX (n=7,20 OD). GNRs were allowed 24 h after
injection to accumulate in tumors, and then all tumors were
irradiated with an NIR laser (Coherent, Santa Clara, CA,
USA) through the skin surface, covering the tumors with
power density of 12 W/cm2 and spot diameter of 10 mm for
2-3 min. Interstitial temperature in the HT29 tumors was
measured with a TRH Central probe (Omega, Stamford,
CN, USA). Laser exposure was immediately stopped if the
temperature reached 60°C. Tumor sizes and body weights
of the mice were measured and recorded for up to 16 days
after laser treatment. Dimensions of the resulting tumors
were measured with digital calipers, and tumor volumes
were calculated as volume = length × width2 /2.
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